Recent advances in pathophysiology and treatment of immune thrombocytopenia

[Rinshō ketsueki] The Japanese journal of clinical hematology
Hirokazu Kashiwagi, Yoshiaki Tomiyama

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia caused by immune-mediated platelet destruction and impairment of platelet production. Recent studies have uncovered details involving the target regions of platelet-associated anti-GPIIb/IIIa antibodies, pathological differences depending on the specificity of target antigens, and cellular abnormalities, especially impairment of regulatory T cells contributing to the pathogenesis of ITP. Treatment of ITP has been changed dramatically by the application of thrombopoietin receptor agonists, TPO-RAs, in patients unresponsive to traditional steroids and splenectomy. Rituximab has also been used in Western countries for ITP patients and its long-term efficacy has become increasingly clear. Clinical problems awaiting solution in ITP management include improving the efficacy of treatments for newly-diagnosed ITP, confirmation of the long-term efficacy and safety of TPO-RAs, and determination of the positioning of rituximab in the treatment sequence of ITP.

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

International Journal of Hematology
Hirokazu Kashiwagi, Yoshiaki Tomiyama
Bulletin de l'Académie nationale de médecine
B Godeau
Transfusion clinique et biologique : journal de la Société française de transfusion sanguine
B Godeau
[Rinshō ketsueki] The Japanese journal of clinical hematology
Gregory Cheng
© 2021 Meta ULC. All rights reserved